Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.38 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.38 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | HPGD | P15428 | 5/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527752 | 0.81 | — | — | |
| SCHEMBL1912667 | 0.80 | CA12 (0.41) | CSNK2A2KDRCSNK2BCSNK2A1ATM | |
| Hydrochloric Acid SCHEMBL9528592 | 0.79 | DAO (0.42) | CSNK2A1KDM4EALDH1A1MAPK1NPC1 | |
| SCHEMBL28316078 | 0.78 | CSNK2A2 (0.41) | CSNK2A2KDRCSNK2BCSNK2A1ATM | |
| SCHEMBL28316585 | 0.78 | KDM4E (0.40) | CSNK2A2KDRCSNK2BCSNK2A1ATM | |
| SCHEMBL28315326 | 0.78 | CFTR (0.38) | CSNK2A2KDRCSNK2BCSNK2A1ATM | |
| SCHEMBL19274421 | 0.78 | KDM4E (0.38) | CSNK2A2KDRCSNK2BCSNK2A1ATM | |
| SCHEMBL27286138 | 0.77 | — | — | |
| SCHEMBL9260259 | 0.75 | — | — | |
| SCHEMBL7134538 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4298097-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230391764-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-12-07 | — | — | US | disclosed |
| CN-116897155-A | Benzothiazolyl bicyclo [1.1.1] pentane derivatives for the treatment and prevention of hepatitis b virus infection | 豪夫迈·罗氏有限公司 | 2023-10-17 | — | — | CN | disclosed |
| WO-2022180003-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2022-09-01 | — | — | WO | disclosed |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | GENENTECH, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH INC (US) | 2021-10-07 | — | — | US | disclosed |
| EP-3700901-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Genentech, Inc. (US) | 2020-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309660-A1 | (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | VHL, MDM2, CUL2 | CSNK2A2 1334/4885KDR 327/4885CSNK2B 1473/4885 |
| US-11242344-B2 | (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof | VHL, MDM2, CUL2 | CSNK2A2 1334/4885KDR 327/4885CSNK2B 1473/4885 |
| US-20230391764-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, SLC10A1, BCL2A1 | CSNK2A2 1380/4885KDR 3621/4885CSNK2B 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.